Allergy Therapeutics plc
AGYTF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | 0.06 | -0.02 | 0.04 |
| FCF Yield | -14.88% | -20.02% | -16.72% | -5.70% |
| EV / EBITDA | -8.36 | -6.37 | -6.33 | -38.32 |
| Quality | ||||
| ROIC | -87.75% | -75.99% | -79.30% | -21.09% |
| Gross Margin | 45.65% | 53.87% | 55.79% | 68.03% |
| Cash Conversion Ratio | 1.01 | 0.82 | 0.69 | 1.14 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.24% | -8.80% | -10.93% | -2.37% |
| Free Cash Flow Growth | -23.54% | -5.93% | -90.11% | -402.35% |
| Safety | ||||
| Net Debt / EBITDA | -1.05 | -0.59 | -0.61 | 1.28 |
| Interest Coverage | -4.21 | -8.58 | -16.24 | -18.30 |
| Efficiency | ||||
| Inventory Turnover | 2.95 | 2.00 | 2.27 | 2.04 |
| Cash Conversion Cycle | 136.62 | 173.30 | 118.46 | 158.03 |